FDAnews
www.fdanews.com/articles/199178-carb-x-awards-gsk-75-million-to-develop-uti-treatment

CARB-X Awards GSK $7.5 Million to Develop UTI Treatment

September 23, 2020

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has granted GlaxoSmithKline (GSK) $7.5 million to develop a drug to treat and prevent recurrent urinary tract infections (UTIs) caused by E. coli bacteria.

The funding will help GSK begin a first-in-human phase 1 study of GSK3882347, which is expected to be completed next year. It will also support scaling up facilities for future clinical and nonclinical studies.

The orally administered drug targets a protein found on the surface of E. coli bacteria. By binding to the protein, it prevents the pathogen from attaching to the bladder wall to cause UTIs.

View today's stories